Loading company…
MultivisionDx develops AI tools to support personalized cancer diagnosis and treatment selection.
MultivisionDx develops AI-based diagnostic tools for personalized treatment decisions in solid cancers. Its spatial biology platform combines tumor and microenvironment features to produce patient-specific profiles for clinicians. Founded in 2025, the company is based in Helsinki, Finland. In December 2025, it raised EUR 1 million in pre-seed funding led by Antler, with Helsinki University Funds and Kaikarhenni Oy participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in